French drug trial leaves one dead and five in critical condition

One person has been left brain dead and five others have been hospitalised after taking part in a clinical trial in France of an experimental drug made by Portuguese drug company Bial, French Health Minister Marisol Touraine said on Friday.

In total, 90 people have taken part in the trial, taking some dosage of the drug aimed at tackling mood and anxiety issues, as well as movement coordination disorders linked to neurological issues, Touraine said.

The six men aged 28 to 49 had been in good health until taking the oral medication at the Biotrial private facility that specialises in clinical trials, she said.

"This is unprecedented," Touraine told a news conference after meeting volunteers and their families in Rennes, western France. "We'll do everything to understand what happened."

Prosecutors have opened an investigation into the case.

The six men started taking the drug on Jan. 7. The brain-dead volunteer was admitted to hospital on Monday, the minister said.

For three of the five others - who went in on Wednesday and Thursday - there are fears of irreversible handicap, doctor Gilles Edan said, though he still hoped that would not be the case. One of the six had no symptoms but was being carefully monitored, he said.

Testing had already been carried out on animals, including chimpanzees, starting in July, Touraine said.

All trials on the drug have now been suspended and all volunteers who have taken part in the trial are being called back, the health ministry added.

The medicine involved is a so-called FAAH inhibitor that works by targeting the body's endocannabinoid system, which is also responsible for the human response to cannabis.

Bial said in a statement it was committed to ensuring the wellbeing of test participants and was working with authorities to discover the cause of the injuries, adding that the clinical trial have been approved by French regulators.

The company said five people, rather than six, had been hospitalised, including one left brain dead, without explaining the discrepancy with the official French figures.

Cases of early-stage clinical trials going badly wrong are rare but not unheard of. In 2006, six healthy volunteers given an experimental drug in London ended up in intensive care. One was described as looking like "the elephant man" after his head ballooned. Another lost his fingertips and toes.

In the initial Phase I stage of clinical testing, a drug is given to healthy volunteers to see how it is handled by the body and what is the right dose to give to patients.

"Undertaking Phase 1 studies is highly specialist work," said Daniel Hawcutt, a lecturer in clinical pharmacology at Britain's University of Liverpool.

Medicines then go into larger Phase II and Phase III trials to assess their effectiveness and safety before they are finally approved for sale.

Europe has strict regulations governing the conduct of clinical trials, with Phase I tests subject to particular scrutiny. But Ben Whalley, a professor of neuropharmacology at the University of Reading, said these could only minimise risks, not abolish them.

"There is an inherent risk in exposing people to any new compound," he said.

The 2006 London trial led to the collapse of Germany's TeGenero, the company developing a medicine known as TGN1412. The drug has since gone back into tests for rheumatoid arthritis and is showing promise when given at a fraction of the original dose.

related articles
The War on Drugs isn\'t working, says Christian Aid
The War on Drugs isn't working, says Christian Aid

The war on drugs is simply not working, according to a new report by Christian Aid.

Mother shares how Jesus rescued her from drug addiction
Mother shares how Jesus rescued her from drug addiction

Psalm 116, an open door and Jesus have rescued Holly Prebble, a young mother and ex-drug addict, from hell.

10 things to look out for in 2016: Part Two

Krish Kandiah looks ahead to what might be in store for the next year.

News
Faith in difficult times: lessons from 1930s Britain
Faith in difficult times: lessons from 1930s Britain

Architectural historian Steven Brindle talks to Christian Today about the faith that shaped 1930s Britain, the churches that supported struggling communities and what lessons the decade might have for us today.

Campaign aims to mobilise 500,000 Christians for Christmas outreach
Campaign aims to mobilise 500,000 Christians for Christmas outreach

Shine Your Light is aiming to mobilise half a million Christians to share the gospel with five million people across the UK this Christmas, with more than 2,000 churches already signed up, organisers say.

The Church of England should repent for previous calls to ban 'conversion therapy'
The Church of England should repent for previous calls to ban 'conversion therapy'

The Church of England's uneasiness about the government's ‘conversion practices’ bill is a perfect lesson in the old adage, 'be careful what you wish for,' writes Dr Martin Davie.

Leaked Home Office report links 'Christian extremism' to traditionalist beliefs and immigration concerns
Leaked Home Office report links 'Christian extremism' to traditionalist beliefs and immigration concerns

An internal Home Office report lists concerns about immigration, multiculturalism and changing social values among the characteristics associated with what it calls "Christian extremism", it has been reported.